ALCAM and neoplasm: There is an evidence that 14G2a antibodies could cross-react with highly glycosylated ALCAM (CD166) adhesion molecule [20], which is expressed in different tissues, mainly on cells of the immune system, and this molecule does not exhibit tumor association.